Abstract:Abstract Background Hepatocarcinogenesis is reportedly correlated with abnormal m6A modifications; however, it is unknown whether m6A RNA methylation regulators facilitate the occurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Thus, we constructed an m6A-related model that may enhance HBV-related HCC prognosis. Methods Gene signatures of HNRNPA2B1 and RBM15 were generated by univariate and Lasso Cox regression analyses using the gene set and clinical information from The Cancer Genome Atlas (TCGA) database. High-risk and low-risk groups were confirmed based on the gene signature model. Furthermore, we validated the predictive roles of the two genes for overall survival (OS) in the GSE14520 dataset. The relative expression of 22 paired mRNAs was measured using quantitative real-time polymerase chain reaction (qRT-PCR) analysis to determine whether the two genes had a predictive role in our Guilin cohort. Results The differences in OS between the high-risk and low-risk groups were statistically significant in the TCGA (p = 0.003) and GSE14520 (p = 0.045) datasets, but not in the Guilin cohort, owing to differences in clinical information among the three cohorts (mainly the TNM stage and survival state). Stratified analysis of TNM stages showed that the two-gene signature acted as a prognostic indicator of HBV-related HCC patients in the early TNM stage; both TCGA and GSE14520 cohorts showed statistical significance. Moreover, multivariate Cox regression analysis indicated that the two-gene signature was an independent factor for predicting prognosis (HR = 1.087, 95% CI: 1.007–1.172). Correlation analysis between the gene signature and clinical features revealed that the risk stratification was significantly correlated with grade and survival state. Finally, Gene Set Enrichment Analysis (GSEA) revealed that the KEGG pathways associated with the cell cycle, DNA replication, the spliceosome, repair, and metabolism-related processes were all significantly enriched in the high-risk group. Among the enriched genes, the expression levels of the replication protein RPA1 and the pre-mRNA splicing factor SF3B1 were significantly upregulated in the high-risk group. These results might help in elucidating the underlying molecular mechanisms of HBV-related HCC. Conclusions Our data may provide new predictive signatures and potential therapeutic targets to identify and treat HBV-related HCC patients in the early disease stage.

HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV‐Related HCC Through Reciprocal Regulation With Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 3

HBcrAgandpgRNAand the therapeutic effect inHBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNAis a powerful predictor of response.

LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer.

Hepatitis B Virus P Protein Initiates Glycolytic Bypass in HBV-related Hepatocellular Carcinoma Via a FOXO3/miRNA-30b-5p/MINPP1 Axis

A Double-Edged Sword: the HBV-induced Non-Coding RNAs Alterations in Hepatocellular Carcinoma

Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma.

Hepatitis B Virus Pregenomic RNA Reflecting Viral Replication in Distal Non-tumor Tissues as a Determinant of the Stemness and Recurrence of Hepatocellular Carcinoma

Role of early on-treatment serum HBV RNA declines in predicting hepatocellular carcinoma risk in patients with chronic hepatitis B

Identification of Long Noncoding RNAs Biomarkers in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy

Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound

Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant

[Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy]

Dynamics of Hepatitis B Virus Pregenomic RNA in Chronic Hepatitis B Patients With Antiviral Therapy Over 9 Years

The Significance of M6a RNA Methylation Regulators in Predicting the Prognosis and Clinical Course of HBV-related Hepatocellular Carcinoma.

Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation Via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells

Hepatitis B Virus Pregenomic RNA Status Can Reveal the Long‐term Prognoses of Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues

Integrated Analysis of Multiple Transcriptomic Data Identifies ST8SIA6‑AS1 and LINC01093 As Potential Biomarkers in HBV‑associated Liver Cancer.

Potentials as biomarker and therapeutic target of upregulated long non-coding RNA HLA-F antisense RNA 1 in hepatitis B virus-associated hepatocellular carcinoma

The significance of detecting HBV pgRNA and HBcrAg in HBV patients treated with NAs

Hepatitis B Virus-Upregulated LNC-HUR1 Promotes Cell Proliferation and Tumorigenesis by Blocking p53 Activity.